Berger Montague Announces Class Action Against Erasca (NASDAQ: ERAS) Over Alleged Securities Fraud
A class action lawsuit has been filed against Erasca, Inc. (NASDAQ: ERAS), alleging securities fraud due to misleading statements about its drug candidate and failure to disclose patent disputes with Revolution Medicines. The stock price dropped over 45% following the disclosure of these issues.
Topics: lawsuit securities fraud stock price drop